Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Sinco Pharmaceuticals Holdings Ltd. ( (HK:6833) ).
Sinco Pharmaceuticals Holdings Ltd. reported an 11.1% increase in revenue to RMB2,821.3 million for the year ending December 31, 2024, driven by higher sales volumes of human albumin solutions. However, the company’s gross profit decreased due to rising costs, leading to a slight decline in net profit to RMB42.0 million. The board proposed a reduced final dividend of HK0.20 cents per share, reflecting a cautious approach amid cost pressures.
More about Sinco Pharmaceuticals Holdings Ltd.
Sinco Pharmaceuticals Holdings Ltd. is a company incorporated under the laws of the Cayman Islands, operating in the pharmaceutical industry. The company primarily focuses on the production and sale of pharmaceutical products, with a significant emphasis on human albumin solutions.
YTD Price Performance: 7.50%
Average Trading Volume: 479,649
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$437.1M
See more data about 6833 stock on TipRanks’ Stock Analysis page.